Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.39 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.39 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | ECE1 | P42892 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 4/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 2/20 | 0.36 |
| ▸ | DPP3 | Q9NY33 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6808926 | 0.92 | MEN1 (0.42) | MEN1KMT2AITGB1ITGA4ITGB7 | |
| SCHEMBL6807386 | 0.90 | ITGB2 (0.43) | ITGB1ITGA4ALDH1A1HSD17B10ACE | |
| SCHEMBL6803199 | 0.90 | ITGB1 (0.40) | MEN1KMT2AITGB1ITGA4ITGB7 | |
| SCHEMBL6812605 | 0.89 | ITGB2 (0.40) | ITGB1ITGA4ITGB7ALDH1A1HSD17B10 | |
| SCHEMBL6808899 | 0.86 | KMT2A (0.41) | MEN1KMT2AITGB1ITGA4ECE1 | |
| SCHEMBL6802705 | 0.85 | KMT2A (0.42) | KMT2AITGB1ITGA4MAPK1 | |
| SCHEMBL6808223 | 0.85 | ITGA4 (0.38) | MEN1KMT2AITGB1ITGA4ITGB7 | |
| SCHEMBL6801508 | 0.84 | ECE1 (0.38) | MEN1KMT2AITGB1ITGA4ITGB7 | |
| SCHEMBL6808082 | 0.83 | ECE1 (0.37) | MEN1KMT2AITGB1ITGA4ITGB7 | |
| SCHEMBL7538530 | 0.83 | ITGB2 (0.48) | MEN1KMT2AITGB1ITGA4ITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040039040-A1 | Urea derivative and adhesive-molecule inhibitor containing the same as active ingredient | TORAY INDUSTRIES, INC. (JP) | 2004-02-26 | — | — | US | disclosed |
| EP-1323709-A1 | UREA DERIVATIVE AND ADHESIVE-MOLECULE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | TORAY INDUSTRIES, INC. (JP) | 2003-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039040-A1 | Urea derivative and adhesive-molecule inhibitor containing the same as active ingredient | ICAM1, VCAM1, EPCAM | MEN1 4217/4885KMT2A 3270/4885ITGB1 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.